Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 7/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440571 | 0.93 | HRH2 (0.49) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL12269994 | 0.92 | HRH2 (0.43) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL19415078 | 0.92 | P2RY1 (0.53) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL12269762 | 0.92 | P2RY1 (0.53) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL12269772 | 0.89 | HRH2 (0.42) | HRH2HTR5AP2RY1P2RY2ADORA3 | |
| SCHEMBL16440590 | 0.85 | P2RY1 (0.52) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL17832220 | 0.85 | P2RY1 (0.53) | HRH2HTR5AP2RY1P2RY2HTR2B | |
| SCHEMBL12269709 | 0.85 | P2RY1 (0.42) | HRH2HTR5AP2RY1P2RY2ADORA3 | |
| SCHEMBL16440587 | 0.85 | ADORA3 (0.48) | HRH2HTR5AP2RY1P2RY2ADORA3 | |
| SCHEMBL19459932 | 0.84 | HRH2 (0.49) | HRH2HTR5AP2RY1P2RY2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526739-B2 | Compositions and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160166591-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | GOOGLE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9303053-B2 | Compositions and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150038463-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | UNIV CONNECTICUT (US) | 2015-02-05 | — | — | US | disclosed |
| US-8822434-B2 | Compositions and methods to treat cardiac diseases | THE UNIVERSITY OF CONNECTICUT (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110212924-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212924-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885P2RY1 4/4885 |
| US-20150038463-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885P2RY1 4/4885 |
| US-20160166591-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885P2RY1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.